The knowledge gained from our basic studies on virus entry and spreading directly translates in identification and development of antiviral drug cocktails optimized for intranasal delivery. The drugs target both the cells and the virus, blocking multiple key steps of the viral life cycle. Our current formulations have shown remarkable efficacy in preventing SARS-CoV-2 lung infection and lung tissue damage in mouse models. Our research team has access to biosafety level 3 facilities, clinical virus isolates, including SARS-COV-2 and all its known variants of concerns, and a large network of collaborators in academia, local hospitals and industry.
We aim at developing a cost effective, safe, and easy to use antiviral therapy to prevent and facilitate recovery from respiratory infections caused by multiple human pathogenic viruses.